Your SlideShare is downloading. ×
Clinical development activity in perspective: A head-to-head comparison of Pharma and CRO phase I-IV activities
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Clinical development activity in perspective: A head-to-head comparison of Pharma and CRO phase I-IV activities

176

Published on

When you think about it, spending on phase I-IV services by pharma sponsors is roughly equivalent to revenue generated by CROs. One company’s expense is another company’s revenue. ISR wanted to see …

When you think about it, spending on phase I-IV services by pharma sponsors is roughly equivalent to revenue generated by CROs. One company’s expense is another company’s revenue. ISR wanted to see how the largest public CROs stacked up to the largest pharma companies in terms of their phase I-IV activities.

- See more at: http://www.isrreports.com/free-resources/clinical-development-activity-perspective/#sthash.7xWDch7f.dpuf

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
176
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Pharma CRO A head-to-head comparison of Pharma and CRO phase I-IV activities. Rank Company Total R&D Development Phase I-IV 1 Novartis $9,727 $6,128 $4,351 2 Roche $9,656 $6,083 $4,319 3 Merck $7,123 $4,487 $3,186 4 Pfizer $6,641 $4,184 $2,971 5 Quintiles $2,920 6 Sanofi $6,420 $4,045 $2,872 7 GSK $5,683 $3,580 $2,542 8 Eli Lilly $5,531 $3,485 $2,474 9 Bayer $4,313 $2,717 $1,929 10 AZ $4,281 $2,697 $1,915 11 Amgen $4,083 $2,572 $1,826 12 BMS $3,715 $2,340 $1,662 13 PAREXEL $1,532 14 Covance $1,494 15 Takeda $3,277 $2,065 $1,466 16 ICON $1,336 17 Otsuka $2,379 $1,499 $1,064 18 Gilead $2,167 $1,365 $969 19 Novo Nordisk $2,120 $1,336 $948 20 Astellas $1,998 $1,259 $894 Methodology When you think about it, spending on phase I-IV services by pharma sponsors is roughly equivalent to revenue generated by CROs. One company’s expense is another company’s revenue. ISR wanted to see how the largest public CROs stacked up to the largest pharma companies in terms of their phase I-IV activities. ISR used the assumptions we generated in developing our 2014 CRO Market Size report to develop a side-by-side comparison of phase I-IV activity between sponsors and CROs. For sponsors: We took their annual R&D spending, multiplied it by 63% to get their development spending, then multiplied that by 71% to get their phase I-IV spending. For CROs: We took just their clinical development revenue (not commer- cial, consulting, preclinical). Is this an exact match, no. However, directionally we find that of the 20 companies performing the most phase I-IV activities, at least four of them are CROs and, if their financials were publicly available, we could have easily included PPD and perhaps PRA, inVentiv Health Clinical, and INC Research in the list. www.ISRreports.com info@ISRreports.com Clinical development activity in perspective (Annual $B USD)

×